3D Medicines, Inc. ( (HK:1244) ) has issued an announcement.
3D Medicines Inc. has announced the lifting of a preservation order on bank accounts related to its subsidiary, following discussions with Qingdao Hainuo. Despite ongoing civil proceedings and a pending court decision regarding the revocation of a previous civil ruling, the company stated that its commercialization efforts for ENWEIDA are not materially impacted. However, the ruling may affect operations and R&D activities, though the company assures that its financial stability remains intact.
More about 3D Medicines, Inc.
YTD Price Performance: -2.92%
Average Trading Volume: 525,889
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$772M
For detailed information about 1244 stock, go to TipRanks’ Stock Analysis page.